LT3679934T - Mažų molekulių trail geno indukcija sveikomis ir vėžinėmis ląstelėmis kaip priešvėžinis gydymas - Google Patents

Mažų molekulių trail geno indukcija sveikomis ir vėžinėmis ląstelėmis kaip priešvėžinis gydymas

Info

Publication number
LT3679934T
LT3679934T LTEP20152317.2T LT20152317T LT3679934T LT 3679934 T LT3679934 T LT 3679934T LT 20152317 T LT20152317 T LT 20152317T LT 3679934 T LT3679934 T LT 3679934T
Authority
LT
Lithuania
Prior art keywords
healthy
small molecules
gene induction
cancer
cancer cells
Prior art date
Application number
LTEP20152317.2T
Other languages
English (en)
Inventor
Wafik El-Deiry
Joshua E. Allen
Gen WU
Original Assignee
The Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47068061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3679934(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Penn State Research Foundation filed Critical The Penn State Research Foundation
Publication of LT3679934T publication Critical patent/LT3679934T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP20152317.2T 2011-04-29 2012-04-30 Mažų molekulių trail geno indukcija sveikomis ir vėžinėmis ląstelėmis kaip priešvėžinis gydymas LT3679934T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
LT3679934T true LT3679934T (lt) 2024-11-11

Family

ID=47068061

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12776073.4T LT2701708T (lt) 2011-04-29 2012-04-30 Maža molekulė, indukuojanti trail geną normaliose ir naviko ląstelėse, kaip priešvėžinė gydymo priemonė
LTEP20152317.2T LT3679934T (lt) 2011-04-29 2012-04-30 Mažų molekulių trail geno indukcija sveikomis ir vėžinėmis ląstelėmis kaip priešvėžinis gydymas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP12776073.4T LT2701708T (lt) 2011-04-29 2012-04-30 Maža molekulė, indukuojanti trail geną normaliose ir naviko ląstelėse, kaip priešvėžinė gydymo priemonė

Country Status (18)

Country Link
US (9) US8673923B2 (lt)
EP (3) EP2701708B1 (lt)
JP (7) JP6132833B2 (lt)
CA (1) CA2832342C (lt)
CY (1) CY1123010T1 (lt)
DK (2) DK3679934T3 (lt)
ES (2) ES2992934T3 (lt)
FI (1) FI3679934T3 (lt)
HR (2) HRP20241214T1 (lt)
HU (2) HUE049207T2 (lt)
LT (2) LT2701708T (lt)
MX (2) MX365365B (lt)
PL (2) PL2701708T3 (lt)
PT (2) PT3679934T (lt)
RS (2) RS60186B1 (lt)
SI (2) SI2701708T1 (lt)
SM (2) SMT202000272T1 (lt)
WO (1) WO2012149546A2 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3679934T (pt) 2011-04-29 2024-09-05 Penn State Res Found Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
CN106163524B (zh) * 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
SMT202400497T1 (it) 2014-03-31 2025-01-14 Scripps Research Inst Farmacoforo per induzione di trail
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
IL295286B2 (en) 2015-01-30 2024-10-01 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy
CN107405428A (zh) 2015-03-31 2017-11-28 北卡罗来纳-查佩尔山大学 干细胞的递送载体及其用途
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3408298B1 (en) 2016-01-29 2024-11-20 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
JP2025527300A (ja) 2022-08-05 2025-08-20 キメリックス インコーポレイテッド 神経膠腫の治療のための薬学的組成物及びその使用
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
KR20080087822A (ko) * 2005-12-16 2008-10-01 제넨테크, 인크. 신경아교종을 진단하고, 예측하고, 치료하는 방법
JP5537035B2 (ja) * 2006-02-10 2014-07-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
CN101511361A (zh) * 2006-06-30 2009-08-19 先灵公司 使用增强p53活性的取代哌啶的方法
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
PE20120559A1 (es) * 2009-06-24 2012-05-21 Stephen Evans-Freke Composicion que comprende al factor liberador de corticotropina
PT3679934T (pt) 2011-04-29 2024-09-05 Penn State Res Found Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.

Also Published As

Publication number Publication date
JP2021185210A (ja) 2021-12-09
RS60186B1 (sr) 2020-06-30
US9072744B1 (en) 2015-07-07
US8673923B2 (en) 2014-03-18
SI2701708T1 (sl) 2020-07-31
PL2701708T3 (pl) 2020-11-02
JP2019019145A (ja) 2019-02-07
WO2012149546A3 (en) 2013-01-03
JP2014514326A (ja) 2014-06-19
HRP20200636T1 (hr) 2020-07-10
SI3679934T1 (sl) 2025-04-30
PT2701708T (pt) 2020-05-08
MX379539B (es) 2025-03-11
JP6132833B2 (ja) 2017-05-24
EP3679934A1 (en) 2020-07-15
PL3679934T3 (pl) 2025-01-07
US9061032B2 (en) 2015-06-23
EP2701708A2 (en) 2014-03-05
US20220288079A1 (en) 2022-09-15
DK2701708T3 (da) 2020-04-27
CA2832342C (en) 2019-12-31
LT2701708T (lt) 2020-05-25
US20170224690A1 (en) 2017-08-10
EP3679934B1 (en) 2024-06-05
US20150265619A1 (en) 2015-09-24
JP7600286B2 (ja) 2024-12-16
MX365365B (es) 2019-05-30
ES2992934T3 (en) 2024-12-19
CY1123010T1 (el) 2021-10-29
USRE46290E1 (en) 2017-01-31
WO2012149546A2 (en) 2012-11-01
US9629842B2 (en) 2017-04-25
EP4335511B1 (en) 2025-11-26
JP2024051080A (ja) 2024-04-10
ES2786033T3 (es) 2020-10-08
DK3679934T3 (en) 2024-07-22
MX2019006379A (es) 2019-09-04
US20150202206A1 (en) 2015-07-23
US20170000790A1 (en) 2017-01-05
JP2025159099A (ja) 2025-10-17
US9452165B2 (en) 2016-09-27
JP2016199580A (ja) 2016-12-01
EP2701708A4 (en) 2015-01-07
EP2701708B1 (en) 2020-01-22
RS65813B1 (sr) 2024-08-30
FI3679934T3 (fi) 2024-07-08
JP2023060196A (ja) 2023-04-27
EP4335511A3 (en) 2024-05-15
SMT202000272T1 (it) 2020-07-08
HUE049207T2 (hu) 2020-09-28
EP4335511A2 (en) 2024-03-13
PT3679934T (pt) 2024-09-05
US20120276088A1 (en) 2012-11-01
MX2013012346A (es) 2014-08-22
HRP20241214T1 (hr) 2024-11-22
HUE068623T2 (hu) 2025-01-28
US20140248264A1 (en) 2014-09-04
US20240415841A1 (en) 2024-12-19
CA2832342A1 (en) 2012-11-01
US12036223B2 (en) 2024-07-16
SMT202400421T1 (it) 2024-11-15

Similar Documents

Publication Publication Date Title
LT3679934T (lt) Mažų molekulių trail geno indukcija sveikomis ir vėžinėmis ląstelėmis kaip priešvėžinis gydymas
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
IL228031B (en) Adno vectors for gene therapy in choroideremia
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
BR112013014076A2 (pt) métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
GB201100180D0 (en) Tumour cell and tissue culture
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
IL228847A0 (en) il1r1 inhibitors and their use in cancer treatment
EP2925308A4 (en) CREBSTARGETING WITH A METABOLIC THERAPY AND HYPERBARIC OXYGEN
IL236573A0 (en) Therapeutic retrieval of targets in biological fluids
IL237411A0 (en) A method for diagnosing and treating cancer that targets molecules expressed in cancer stem cells
EP2734042A4 (en) TARGETING OF GLI PROTEINS IN HUMAN CANCER BY SMALL MOLECULES
PT2831110T (pt) Terapia anti-emp2 reduz as células-tronco do cancro
EP2882869A4 (en) PROSTATE CANCER GENE EXPRESSION PROFILE
EP2763658A4 (en) CELLIPOSOMAS IN CANCER THERAPY
PL2948144T3 (pl) Celowanie w białka gli w ludzkich nowotworach złośliwych małymi cząsteczkami
GB201106630D0 (en) Cancer therapy
GB201108085D0 (en) Novel cancer therapies and methods
GB201100873D0 (en) Gene targeting in animals
GB201118220D0 (en) Cancer therapy
GB201201397D0 (en) Gene targeting in animals
AU2012266896A1 (en) Scaffold-kinase interaction blockades and uses thereof in treating cancer